UFPT Stock Analysis: UFP Technologies | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 2.329m USD | 12M Return: 50.1% | US9026731029 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 31.5M
EPS Trend: 95.5%
Qual. Beats: 11
Rev. Trend: 97.1%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
UFP Technologies, Inc. (NASDAQ: UFPT) is a U.S.-based designer and manufacturer of engineered custom products, with a primary focus on medical devices and sterile packaging. Its medical portfolio includes protective drapes for robotic surgery, wound care and infection prevention products, sterile packaging for medical devices and orthopedic implants, components for cardiac implants, dispenser coils for catheters, and biopharma drug manufacturing solutions.
Beyond healthcare, the company serves aerospace and defense, automotive, consumer, electronics, and industrial markets with offerings such as protective packaging for firearms and drones, acoustic and thermal insulation, filtration media, seals and gaskets, tactical and sports padding, and automotive trim components. The company sells through a direct sales force, was founded in 1963, and is headquartered in Newburyport, Massachusetts. Within the GICS classification, UFPT is categorized in the Health Care sector under the Health Care Supplies sub-industry, reflecting its medical orientation despite a diversified end-market footprint.
- Medical device segment drives margin expansion and revenue growth
- Defense and aerospace packaging demand rises with drone production
- Acquisitions expand specialty medical product capabilities and capacity
| Net Income: 72.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -2.42 > 1.0 |
| NWC/Revenue: 24.79% < 20% (prev 20.76%; Δ 4.03% < -1%) |
| CFO/TA 0.10 > 3% & CFO 71.6m > Net Income 72.3m |
| Net Debt (146.3m) to EBITDA (110.5m): 1.32 < 3 |
| Current Ratio: 3.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (7.80m) vs 12m ago 0.30% < -2% |
| Gross Margin: 28.50% > 18% (prev 28.76%; Δ -0.26% > 0.5%) |
| Asset Turnover: 95.95% > 50% (prev 92.74%; Δ 3.22% > 0%) |
| Interest Coverage Ratio: 12.41 > 6 (EBIT TTM 96.4m / Interest Expense TTM 7.77m) |
| A: 0.23 (Total Current Assets 234.9m - Total Current Liabilities 78.3m) / Total Assets 681.9m |
| B: 0.61 (Retained Earnings 413.2m / Total Assets 681.9m) |
| C: 0.15 (EBIT TTM 96.4m / Avg Total Assets 658.3m) |
| D: 2.11 (Book Value of Equity 462.4m / Total Liabilities 219.5m) |
| Altman-Z'' = 6.68 = AAA |
| DSRI: 1.26 (Receivables 117.4m/86.6m, Revenue 631.6m/588.6m) |
| GMI: 1.01 (GM 28.76% / 28.50%) |
| AQI: 0.98 (AQ_t 0.54 / AQ_t-1 0.56) |
| SGI: 1.07 (Revenue 631.6m / 588.6m) |
| TATA: 0.00 (NI 72.3m - CFO 71.6m) / TA 681.9m) |
| Beneish M = -2.76 (Cap -4..+1) = A |
As of October 11, 2026, the stock is trading at USD 288.97 with a total of 92,649 shares traded. Over the past week, the price has changed by -3.90%, over one month by +3.73%, over three months by +15.72% and over the past year by +50.09%.
Current recommended Stop Loss: 270.50 (which is 6.4% or 2.2 ATR below the current price).
UFP Technologies has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold UFPT.
- StrongBuy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 355 | 22.9% |
P/E Trailing = 32.5433
P/E Forward = 21.8341
P/S = 3.6875
P/B = 4.7772
P/EG = 3.8011
Revenue TTM = 631.6m USD
EBIT TTM = 96.4m USD
EBITDA TTM = 110.5m USD
Long Term Debt = 104.8m USD (from longTermDebt, last quarter)
Short Term Debt = 17.2m USD (from shortTermDebt, last quarter)
Debt = 155.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 19.0m
Net Debt = 146.3m USD (calculated: Debt 155.4m - CCE 9.04m)
Enterprise Value = 2.48b USD (2.33b + Debt 155.4m - CCE 9.04m)
Interest Coverage Ratio = 12.41 (Ebit TTM 96.4m / Interest Expense TTM 7.77m)
EV/FCF = 40.30x (Enterprise Value 2.48b / FCF TTM 61.4m)
FCF Yield = 2.48% (FCF TTM 61.4m / Enterprise Value 2.48b)
FCF Margin = 9.72% (FCF TTM 61.4m / Revenue TTM 631.6m)
Net Margin = 11.45% (Net Income TTM 72.3m / Revenue TTM 631.6m)
Gross Margin = 28.50% ((Revenue TTM 631.6m - Cost of Revenue TTM 451.6m) / Revenue TTM)
Gross Margin QoQ = 29.27% (prev 28.77%)
Tobins Q-Ratio = 3.63 (Enterprise Value 2.48b / Total Assets 681.9m)
Interest Expense / Debt = 5.00% (Interest Expense 7.77m / Debt 155.4m)
Taxrate = 18.44% (16.3m / 88.6m)
NOPAT = 78.6m (EBIT 96.4m * (1 - 18.44%))
Current Ratio = 3.00 (Total Current Assets 234.9m / Total Current Liabilities 78.3m)
Debt / Equity = 0.34 (Debt 155.4m / totalStockholderEquity, last quarter 462.4m)
Debt / EBITDA = 1.32 (Net Debt 146.3m / EBITDA 110.5m)
Debt / FCF = 2.38 (Net Debt 146.3m / FCF TTM 61.4m)
Total Stockholder Equity = 432.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.98% (Net Income 72.3m / Total Assets 681.9m)
RoE = 16.72% (Net Income TTM 72.3m / Total Stockholder Equity 432.3m)
RoCE = 17.95% (EBIT 96.4m / Capital Employed (Equity 432.3m + L.T.Debt 104.8m))
RoIC = 12.85% (NOPAT 78.6m / Invested Capital 611.8m)
WACC = 10.90% (E(2.33b)/V(2.48b) * Re(11.35%) + D(155.4m)/V(2.48b) * Rd(5.00%) * (1-Tc(0.18)))
Discount Rate = 11.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 83.52 | Cagr: 0.34%
[DCF] Terminal Value 64.23% ; FCFF base≈65.9m ; Y1≈57.8m ; Y5≈46.7m
[DCF] Fair Price = 49.40 (EV 529.0m - Net Debt 146.3m = Equity 382.7m / Shares 7.75m; r=10.90% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 95.46 | EPS CAGR: 26.11% | SUE: 3.31 | # QB: 11
Revenue Correlation: 97.09 | Revenue CAGR: 22.38% | SUE: 3.10 | # QB: 1
EPS current Quarter (2026-09-30): EPS=2.69 | Chg30d=-2.01% | Revisions=-40% | Analysts=4
EPS current Year (2026-12-31): EPS=10.62 | Chg30d=+2.26% | Revisions=+50% | GrowthEPS=+8.8% | GrowthRev=+9.1%
EPS next Year (2027-12-31): EPS=11.87 | Chg30d=+1.58% | Revisions=+50% | GrowthEPS=+11.8% | GrowthRev=+6.2%
[Analyst] Revisions Ratio: +36% (up=6, down=2)